» Articles » PMID: 28554223

Outpatient Management of Severe Ovarian Hyperstimulation Syndrome: a Systematic Review and a Review of Existing Guidelines

Overview
Date 2017 May 31
PMID 28554223
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of assisted reproductive treatment. Management of women with severe OHSS has traditionally included hospitalisation for close monitoring and supportive treatment. The aim of this review is to assess the evidence for safety and efficacy of outpatient management of severe OHSS. A systematic review of studies describing outpatient management options was performed. Current guidance from advisory bodies was also reviewed. Outpatient management has been found in observational studies to be safe and cost-effective compared to inpatient management. Paracentesis of ascitic fluid seems to be effective treatment for severe OHSS along with supportive management including maintenance of fluid balance and preventative measures against thrombo-embolism. GnRH antagonist was shown in few studies to be effective in treatment of early severe OHSS although further research is required to assess its role in this context. Appropriate outpatient set up and protocols are essential to provide safe outpatient management for women with severe OHSS.

Citing Articles

[The best evidence for the management of ovarian hyper-stimulation syndrome in patients undergoing assisted reproductive therapy].

He Y, Wang Z, Zhang Y, Jiang X, Shen X, Xu M Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(5):632-640.

PMID: 39319473 PMC: 11528148. DOI: 10.3724/zdxbyxb-2024-0349.


Severe ovarian hyperstimulation syndrome following sole gonadotropin-releasing hormone (GnRH) agonist trigger: a case series and literature review.

Berkovitz-Shperling R, Samara N, Meir R, Dominsky O, Azam F, Feferkorn I Arch Gynecol Obstet. 2024; 310(5):2297-2304.

PMID: 39302412 PMC: 11485447. DOI: 10.1007/s00404-024-07740-7.


Outpatient paracentesis for the management of ovarian hyperstimulation syndrome: study protocol for the STOP-OHSS randomised controlled trial.

White D, Pye C, Ridsdale K, Dimairo M, Mooney C, Wright J BMJ Open. 2024; 14(1):e076434.

PMID: 38262643 PMC: 10806818. DOI: 10.1136/bmjopen-2023-076434.


Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.

Ates C, Dilbaz B, Ergani S, Atabay F Rev Assoc Med Bras (1992). 2023; 69(11):e20230789.

PMID: 37909622 PMC: 10610771. DOI: 10.1590/1806-9282.20230789.


A case report of Ovarian hyperstimulation syndrome and corpus luteum rupture in twin pregnancies with IVF-ET.

Luo Y, Shen H, Li H, Tan Z, Chen C, Chen W Medicine (Baltimore). 2023; 102(27):e34238.

PMID: 37417637 PMC: 10328692. DOI: 10.1097/MD.0000000000034238.